Order Book Exceptional, Margins Pressured Near-Term—Hold for Deal Ramps
Revenue rocketed 50% YoY and order book hit an all-time $2.23B, but profit growth lagged at 49% YoY and fell 20% quarter-on-quarter due to $24M in integration and hedge costs. The debate is whether large deals announced can restore margins as costs normalize.
₹531.7 Cr
+49.2% YoY, -20.2% QoQ
~₹200 Cr
$6.5M integration + $10M hedge + $14M MTM
~₹730 Cr
Implied underlying +60%+ YoY
Coforge delivered a quarter that splits sharply between headline and substance. Revenue grew 50% YoY to ₹5,528 Crore and order book hit an all-time $2.23B—both strong. But profit growth (49% YoY) lagged revenue, and worse, profit fell 20% quarter-on-quarter despite revenue climbing 24% QoQ. The gap is ₹200 Crore in one-time and integration costs: ₹43 Crore in acquisition/exceptional items, ₹83 Crore in realized hedge losses, and ₹74 Crore in mark-to-market hedge impacts. Strip these out and normalized profit growth approaches 60%+ YoY—organic and clean. The question is whether margins recover as these costs wind down and large deals ramp.
Where the margin compression came from
Management flagged the timing clearly on the call. CFO Saurabh Goel noted: "Exceptional expenses and acquisition-related expenses recognized during the current quarter amounted to $6.5 million, compared with $5.4 million in Q4. We expect marginal integration costs in Q2 and none from Q3 onwards." The forex hedge position added $10 Crore of realized loss in Q1 and $14 Crore of mark-to-market loss (to crystallize Q2–Q3 as hedges unwind). Stripped of these, EBIT margin was clean 16.0% consolidated (Coforge standalone 16.7%), ahead of the 15.5% FY27 guidance. But the Q1 reported EBIT of 16.0% also benefited from just two months of Encora at a 19.1% EBIT rate—a honeymoon margin that may not hold for a full quarter.
Management's claims vs. what holds up
Revenue up 49% YoY; organic growth 5.2% CC sequential ex-closures
₹5,527.7 Cr delivered (+49.9% YoY); organic CC 1.1% reported, 5.2% ex-India govt/data center exits
Supported
PAT up 110% YoY; NPM expansion 271 bps
Consolidated PAT +49.2% YoY delivered; NPM 9.6% vs implied 6.5% prior (≈300+ bps expansion). 110% figure appears standalone/adjusted
Overstated (headline confusion)
Consolidated EBIT 16.0%, meeting/exceeding 15.5% FY27 guidance
16.0% confirmed; but Q1 includes only 2 months of Encora at 19.1%, masking 2–3 quarters of dilution from integration costs
Supported but with asterisk
Order book $2.23B, +44.2% YoY; 4 large deals signed
$2.23B vs $1.55B year ago; 4 large deals substantiated ($158M ramped, $230M announced for Q2)
Supported
Encora integration 40% G&A cost reduction achieved
G&A reduced from 10% to 6.6% combined; 45 legal entities migrated to SAP by May 1; delivered 19.1% EBIT
Supported
What changed on this call
Order book +44% YoY (vs 30% prior expectation) — exceeds guidance
EBIT 16.0% Q1 ahead of 15.5% FY27 target, but standalone Coforge 16.7% (within guidance), Encora 19.1% (honeymoon)
Encora synergies realized faster than guided (40% G&A cut by Q1, not Q3)
AI revenue mix 86% vs 80% target — exceeds prior guidance
Organic CC sequential growth soft at 1.1% reported (5.2% ex-closures) — below 20%+ historical CAGR
Market positioning & institutional flows
The stock rallied +10.3% on day 1 of the result announcement (Jul 27) and held strength to a +14.3% gain by day 3. At ₹1,721 as of Jul 31, the stock sits 11.9% above its 20-day SMA (₹1,543), 16.2% above its 50-day SMA (₹1,480), and 13.5% below its all-time high (₹1,990). RSI at 70.8 signals overbought territory. Volume is increasing, suggesting interest, but institutional ownership tells a different story.
Foreign institutional investors trimmed 7.33 percentage points in Q1 FY27 (from 30.65% in Q4 to 23.32% now), and domestic institutions also pulled back 11.76pp (56.19% to 44.43%). This is institutional selling into the strength—a bearish signal. Smart money is often early on exits, and the magnitude of FII reduction suggests a deliberate trim rather than passive rebalancing. The narrative makes sense: Coforge delivered a strong order book and beat EBIT guidance, but large deals are unproven revenue (ramps 'mostly start Q3+'), organic growth is soft, and valuation at near-ATH offers limited margin of safety.
The bull-bear ledger
Order book at all-time $2.23B; +44% YoY (beat 30% expectation)
Revenue growth 50% YoY beats IT services peers and prior guidance
EBIT 16.0% consolidated ahead of 15.5% FY27 target (standalone 16.7% strong)
Encora integration ahead of plan (40% G&A cut, 19.1% EBIT in 2 months)
AI revenue 86% of mix (vs 80% target); 11,000 practitioners; 130+ agents deployed
PAT growth 49% YoY lags revenue 50% YoY; underlying margin dilution signal
QoQ PAT fell 20% despite 24% QoQ revenue growth—margin compression
Organic CC sequential growth 1.1% reported (5.2% ex-closures) soft; well below 20% historical CAGR
Large deal ramps 'mostly start Q3+'—revenue upside 2+ quarters away
FII ownership down 7.33pp, DII down 11.76pp in Q1—institutional trim into strength
Valuation near all-time high (₹1,721 vs ₹1,990 ATH); RSI 70.8 overbought
Encora EBIT 19.1% in 2-month window; full-quarter sustainability unproven
Risks ranked by holder concern
Large deal ramp execution
HighFour Q1 deals + $230M Q2 deal ramp 'mostly Q3+'. Revenue recognition depends on FTE deployment pace and customer acceptance. If ramps slip or require deeper discounting, revenue guidance and margin recovery both miss. Stock repriced lower on delayed accretion.
Margin normalization timeline uncertain
HighQoQ PAT -20.2% due to $24M one-time/integration costs. Management guided 'marginal costs Q2, none Q3+' but hedge impacts persist through Q3. If timeline slips or deals land at lower margins, 15.5%+ EBIT guidance at risk.
Encora full-quarter margin unproven
HighQ1 included only 2 months of Encora at 19.1% EBIT—likely a honeymoon period. $480M customer relationship intangibles generate $40M/year amortization (2% permanent EBIT drag). If Encora normalized margin is 16–17% (vs 19%), blended consolidation offers little upside vs standalone Coforge 16.7%.
Organic growth moderation
MediumStandalone CC sequential growth 1.1% (5.2% ex-closures) far below historical 20%+ CAGR and below 'robust growth' narrative. Suggests base business softness; reliance on large deals for growth. If discretionary spending slows industry-wide or deal ramps compress, full-year guidance at risk.
Valuation multiple compression
MediumStock at ₹1,721 near all-time high (₹1,990), priced for flawless execution of 15%+ EBIT and 20%+ revenue growth. Institutional trim (FII -7.33pp, DII -11.76pp) suggests smart money repositioning. If execution falters or growth narrative breaks, multiple compression amplifies downside.
Forex hedge impacts persist
MediumQ1 hedge losses totaled $24M ($10M realized, $14M MTM). Remaining $14M MTM to crystallize Q2–Q3 adds drag to reported profit. If forex continues volatile, hedge costs may extend beyond guidance and pressure near-term reported PAT.
What to watch next
1 · Q2 large deal ramp revenue realization
The $230M multi-year deal signed for Q2 and the $158M deal already ramped are the lynchpins of the growth narrative. Watch for deal revenue recognition pace (FTE deployment, phase completions) and gross margin profile. If Q2 sequential growth accelerates toward 5%+ CC (organic, ex-closures) and ramp margins hold above 16%, the deal thesis gains credibility. Failure to ramp signals execution risk.
2 · Integration cost normalization
CFO guided 'marginal' integration costs Q2 and 'none' from Q3. Watch Q2 reported EBIT for the $24M one-time/hedge drag to recede and PAT to expand sequentially despite seasonal headwinds. If integration costs persist or exceed guidance, margin recovery timeline extends and FY27 15.5%+ guidance narrows.
3 · Encora full-quarter profitability and order book
Q1 gave only 2 months of Encora data; Q2 will be the first full quarter. Watch for standalone EBIT margin to sustain above 17% (vs honeymoon 19.1%) and for management to share order book/large client scaling updates (e.g., Encora clients advancing into $50M+ buckets). This clarifies whether Encora acquisition delivers accretion or becomes a drag.
The honest read
Coforge is not broken. Order book at all-time $2.23B, AI positioning strong, and Encora integration ahead of plan are all genuine wins. But Q1 profit growth (49% YoY) lagged revenue growth (50% YoY) and QoQ profit fell 20%, signaling that near-term margins are genuinely pressured. This is a 'Hold' rating—the bull case depends on large deals ramping on schedule and one-time costs normalizing by Q3–Q4. Management's track record is solid (21.7% revenue CAGR over 9 years), but organic growth this quarter was soft (1.1% CC sequential) and institutional investors are trimming positions at near-ATH valuations. Risk/reward at ₹1,721 is balanced-to-cautious.
The number to track from here: Standalone Coforge EBIT margin ex-Encora. Management's reaffirmed 16.5–17% guidance for FY27 is achievable if large deals ramp and one-time costs wind down, but the margin ceiling is 16.7% (where Coforge standalone landed in Q1). If that erodes below 16.5% as deals scale and costs persist, the 'exceptional' FY27 narrative cracks. Watch Q2 for clarity on whether integration costs truly recede and whether deal ramps offset any further organic softness.
Coforge delivered a steady execution quarter—strong order book, solid margins, and Encora integration on track—but it was not a step-change. Revenue beat, profit lagged, and large deals remain 1–2 quarters away from meaningful revenue recognition. Institutional trim and near-ATH valuation leave no room for stumbles. Holders should stay for the large deal catalysts (Q2–Q3 ramps) and margin recovery (Q3–Q4 normalization), but new money should wait for clarity on organic growth stabilization or a valuation pullback below ₹1,600.
Coforge Q1 FY27: Consolidated PAT +110% YoY (adjusted) on Encora, margins flat, QoQ dips
PAT +63.4% YoY · revenue +49.9% · margins compressing
₹5,527.7 Cr
+49.9% YoY
₹518.6 Cr
+63.4% YoY
9.34%
-0.3pp YoY
₹12.34
Coforge's consolidated (primary) revenue for Q1 FY27 was ₹5,527.7 Cr, up 49.9% YoY and 24.2% QoQ — largely because this is the first full quarter consolidating Encora (acquired April 23, 2026), which contributed ₹957.9 Cr of revenue and ₹157.8 Cr of PAT for its post-acquisition stub period and isn't comparable to the year-ago base. Reported PAT (owners' share) was ₹518.6 Cr. On a raw basis — including the year-ago quarter's ₹70.2 Cr one-off discontinued-operations gain in the base — that's +63.4% YoY; on the continuing-operations basis the company itself uses, stripping that one-off from the base, growth is ~+109.8% YoY, matching the ~110% figure in Coforge's own results commentary. QoQ, PAT actually fell 15.3% from ₹612.3 Cr in Q4 FY26.
Q1 FY-2027 vs prior quarters
The margin story is more muted than the headline PAT growth suggests. Consolidated EBIT margin was 16.0% (₹882.2 Cr EBIT / ₹5,527.7 Cr revenue) — above the company's stated FY27 guidance of 15.5%, but down from 18.5% in Q4 FY26 and only marginally ahead of ~15.0% a year ago. Net profit margin was 9.4% (owners' PAT basis), essentially flat YoY (9.6% a year ago) but down sharply from 14.9% in Q4 FY26. The QoQ squeeze traces to a ₹63.3 Cr amortisation charge on intangibles created in the Encora business combination (a new, quarter-specific item), a net exceptional charge of ₹55.0 Cr (₹61.3 Cr Encora acquisition/integration costs and a ₹10.8 Cr provision against a bankrupt customer's receivable, partly offset by a ₹22.1 Cr forex gain on the Bolivian currency devaluation), and a normalising effective tax rate — Q4 FY26's unusually low tax (₹41.2 Cr on ₹625.0 Cr PBT, aided by a large deferred-tax credit) had inflated that quarter's PAT, making this quarter's QoQ decline look larger than the underlying operating trend.
The stock went into the print at ₹1,721, up 19.4% over the past month of trading.
For context: revenue is at a 6-quarter high.
Management is on track to achieve its 14% EBIT guidance for FY2026, with a strong Q4 expected to deliver a 15% EBIT margin. The company forecasts an 'exceptional' FY2027, driven by a record order book up 30% YoY, strong large deal momentum, and the strategic acquisition of Encora which is expected to accelerate growth.
— This quarter: beat
No Street consensus PAT figure could be confirmed with certainty: one pre-result preview (Univest) cited a brokerage estimate near ₹510 Cr, but that reflected only the organic, pre-Encora business and isn't directly comparable to the reported, Encora-inclusive ₹518.6 Cr — so vs-Street is marked unknown rather than guessed. Against management's own guidance, this is a beat/on-track print: the prior concall had flagged a 14% FY26 EBIT target (Q4 expected at 15%) and an 'exceptional' FY27 with continued margin expansion; this quarter's 16.0% EBIT margin clears the company's subsequently-stated FY27 guidance of 15.5%, and EPS grew 67.2% YoY (₹12.34 vs ₹7.38) despite ~9.4 Mn new shares issued for Encora — consistent with management's claim the deal would be non-dilutive to EPS. By geography, Americas (₹3,417.8 Cr revenue, ₹606.1 Cr EBIT) and EMEA (₹1,492.4 Cr revenue, ₹255.7 Cr EBIT) led growth. The quarter also carried a cluster of corporate actions: an interim dividend of ₹4/share (record date August 3, 2026), re-appointment of OP Bhatt as Chairperson for a second five-year term, in-principle board approval to set up a China entity (financial details awaited), and the launch of 'Momentum AI' for enterprise AI execution. No standalone management press-release text was available in context to cross-check against these figures; external news coverage attributes to the CEO a view of FY27 as an 'exceptional year,' consistent with the prior concall's very-optimistic framing.
W1
FY27 EBIT margin guidance of 15.5% — Q1 came in at 16.0%, down from 18.5% in Q4 FY26; watch whether Encora integration costs keep compressing it sequentially.
W2
Executable 12-month order book of $2.23 Bn (+44% YoY) and $691 Mn of fresh TCV — watch conversion pace into revenue over the next 2-3 quarters.
W3
China entity setup approved in-principle with no financial details yet — watch for capital commitment/timeline disclosure next quarter.
Rs. in Mn in source, converted to Cr (÷10); consolidated PAT ₹518.6 Cr is owners-attributable (total incl. ₹13.1 Cr NCI = ₹531.7 Cr, which reconciles exactly to PBT−tax); Encora (acquired Apr 23, 2026; contributed ₹957.9 Cr revenue/₹157.8 Cr PAT) and a Cigniti-merger restated base make YoY not like-for-like; net exceptional charge ₹55.0 Cr consol / ₹46.4 Cr standalone.
Record order book drives long-term upside; near-term margins pressured by integration
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 7/10
Grade B
Hit 15.5% EBIT guidance in Q1 (delivered 16.0% consolidated), but standalone Coforge at 16.7% masks 2-month Encora contribution. Prior FY26 guidance reaffirmed. One-time costs ($24M Q1) acknowledged and expected to decrease Q2+. Order book track record strong.
Optimistic
next 1–2 quarters
Very Optimistic
multi-year
Coforge delivered revenue growth (+50% YoY) and order book momentum ($2.23B, +44% YoY) ahead of peers, supported by strong AI positioning (86% revenue). However, near-term margins are pressured by Encora integration costs ($6.5M/quarter) and hedge losses ($10M Q1, $14M MTM), causing QoQ PAT to decline 20.2% despite 49.9% YoY revenue growth. PAT growth (49.2% YoY) lags revenue growth, signaling margin headwinds. Management reaffirmed 15.5%+ EBIT guidance for FY27 (already at 16.0% in Q1, but this includes only 2 months of Encora at 19% EBIT, masking near-term dilution). Key risk: deal ramps (especially $230M deal signed for Q2) must execute on schedule to justify current growth narrative; margin recovery dependent on integration cost normalization by Q3.
₹5527.7 Cr
Revenue · +49.9% YoY₹531.7 Cr
Reported PAT · +49.2% YoYCompressing
Margins · vs guidance: MixedDid the claims hold up?
Revenue up 49% YoY; organic growth 5.2% CC sequential ex-closures
MET₹5527.7 Cr delivered (+49.9% YoY); organic CC growth 1.1% reported, 5.2% ex-India govt/data center exits
Combined entity Q1 EBIT 16.0%, meeting/exceeding 15.5% FY27 guidance
METConsolidated EBIT 16.0% confirmed; standalone Coforge 16.7%; but Q1 includes only 2 months Encora ($100.7M revenue at 19.1% EBIT)
PAT up 110% YoY; NPM expansion of 271 bps
OVERSTATEDDelivered PAT growth 49.2% YoY; NPM 9.6% vs likely ~6.5% prior year (implied 300+ bps expansion, not 271). Management's 110% figure appears standalone/adjusted; consolidated delivered is 49.2%
Order book $2.23B, +44.2% YoY; 4 large deals signed in Q1
METOrder book confirmed at $2.23B vs $1.55B year ago; 4 large deals signed substantiated (e.g., $158M deal ramped, $230M deal announced for Q2)
Encora integration ahead of plan; 40% G&A cost reduction achieved
METEncora G&A reduced from 10% to 6.6% combined (40% reduction confirmed); all 45 legal entities migrated to SAP S/4HANA by May 1; delivered 19.1% EBIT vs expected margin accretion
Earnings quality
What changed since the last call
Order book +44% YoY (vs 30% prior guidance)
UpgradePrior FY26 guidance expected order book +30%; delivered $2.23B is +44% YoY vs $1.55B year ago. Four large deals signed in Q1 + $230M deal announced; deal momentum exceeding expectations.
EBIT margin guidance maintained, Q1 ahead
UpgradePrior guidance 15.5% consolidated FY27 EBIT; Q1 delivered 16.0% (40 bps ahead). Standalone Coforge 16.7% (vs 16.5-17% guidance range, at top end). But diluted by Encora 2-month contribution and integration costs.
Encora synergies realized faster than guided
UpgradePrior guidance expected Encora margin accretion by Q3; delivered 40% G&A cost reduction by Q1, 19.1% EBIT within 2 months, ahead of integration playbook. System migrations (SAP S/4HANA) completed by May 1.
PAT growth narrative tempered by one-time costs
NeutralPrior guidance 'exceptional' FY27 growth; Q1 delivered 49.2% PAT YoY growth (strong), but QoQ declined 20.2% due to $24M one-time/integration costs. Normalized for comparability, underlying growth solid but not exceptional near-term.
AI revenue mix exceeded; 86% vs 80% target
UpgradePrior Encora announcement indicated 80% AI-led revenue (Engineering, Data, Cloud); delivered 86% in Q1, driven by Encora's 100% engineering mix (no cloud revenues). Mix quality higher than guided.
The Q&A
Analyst questions focused on three themes: (1) whether 5.2% organic growth would continue (pushed back: no hard guidance, expecting 'robust' Q2 but dependent on deal ramps); (2) margin-vs-growth trade-off (defended: solution-led selling doesn't warrant discounting, can achieve both; already at 16% EBIT and targeting industry-leading margins); (3) Encora order book trajectory (deflected: only 2 months data, will share Q2 update; overall pipeline 'robust'). Management held firm on guidance, acknowledged one-time costs, deflected on specific deal-by-deal profitability. Tone professional but slightly defensive on margin compression justification.
Order intake composition — Sulabh Govila, Morgan Stanley
Answered$691M is standalone Coforge organic only (excludes Encora). UK framework agreements still not included; will sit on top of reported order intake. $230M deal (announced post-call) also not in this number.
Large deal revenue ramp timing — Sulabh Govila, Morgan Stanley
AnsweredQ2 will be robust; many deals already closed in first month; ramps mostly start Q3+. Expected sequential 5.2% CC growth in Q1 ex-closures; Q2 should be very robust despite most ramp benefit delayed.
AI monetization & platforms — Abhishek Pathak, Motilal Oswal
PartialNuuron is operating layer, not standalone platform. 30% of active engagements infused with AI assets. 86% revenue is AI-led (Engineering, Cloud, Data). 6-7% of revenue from outcome-based contracts. Cannot isolate platform-only revenue; blended into service lines.
Margin-growth tradeoff — Abhishek Pathak, Motilal Oswal
AnsweredSolution-led selling doesn't warrant price discounting. Targeting industry-leading growth (third-year running) AND highest margin mid-cap simultaneously; both possible. Standalone Coforge 16.7% EBIT, consolidated 16%.
Enterprise AI adoption vs industry trends — Vibhor Singhal, Nuvama Equities
AnsweredSmart enterprises avoiding lock-in to single LLM/cloud; moving to sovereign/open AI. Service offerings around token ops, security partnerships (Zscaler Guardian AI). Our edge is applied AI in complex domains, not model ownership. Context > models.
Encora large client opportunity — Prateek Maheshwari, HSBC
AnsweredOne Encora client already in top 10 (scalable to $50M+ in 12-18 months). Two accounts in 11-20 range (e.g., Travel portfolio, can scale rapidly). Execution discipline and cross-selling will drive scaling.
G&A cost structure post-acquisition — Ravi Menon, Axis Capital
AnsweredG&A down as % of revenue (6.6% combined vs 6.7% Coforge + 10% Encora). Absolute increase due to Encora consolidation; 40% Encora G&A reduction already achieved. Further reduction expected in Q2.
FCF seasonality improvement — Vibhor Singhal, Nuvama Equities
AnsweredStructurally improved FCF trajectory over 2-3 years (H1 historically near zero; now strong). Confident trend will continue; targeting 100%+ FCF-PAT for FY27.
Working capital and NWC trends — Sulabh Govila, Morgan Stanley
AnsweredAbsolute increase is Encora consolidation; days have actually come down. No structural working capital deterioration.
Outcome-based contract pricing — Aditi Patil, ICICI Securities
AnsweredThree models: (1) legacy modernization on risk basis (lower effort revenue, supernormal post-success profits via Forge-X/Nuuron); (2) subscription model for Mod Squads (monthly, flex FTEs/agents); (3) tech/business outcome-tied models. 6-7% of revenue.
Encora order book and ramp timeline — Divyesh Mehta, Invesco India
PartialOnly 2-month Encora data ($100.2M revenue); order intake was robust, pipeline robust. Not enough data to divvy separately. Margins already indistinguishable (40% G&A cut). Revenue growth indistinguishable by Q3 (not 4 quarters; 2 quarters).
Guidance
FY27 'exceptional growth' (no specific %), order book +44% YoY ($2.23B)
HighQ1 delivered 49.9% YoY revenue growth. Order book significantly ahead of 30% prior expectation. Four large deals signed Q1, $230M deal announced Q2. Large deal ramps Q2-Q3 expected to drive full-year momentum
Consolidated EBIT 15.5%+ FY27 (Q1 delivered 16.0%)
HighStandalone Coforge 16.5-17% (Q1 at 16.7%); Encora 19.1% EBIT (Q1, 2 months). Guidance reaffirmed despite one-time integration costs ($6.5M Q1) and hedge impacts ($24M). Encora synergies delivering; G&A now 6.6% combined
EBITDA 20.5-21% consolidated FY27 (inferred Q1 ~18-19%)
MediumGuidance consistent with prior call. Q1 impacted by $40M/year intangible amortization (customer relationship intangibles from Encora $480M amortized 12yr). Margin sustainable if deal ramps and cost normalization execute
No explicit capex guidance; FCF guidance 100%+ FCF-PAT
HighQ1 delivered 95.3% FCF-PAT conversion (vs -56.5% prior year). Structural WC improvement targeting 100%+ for FY27. No major capex requirements flagged; asset-light model maintained
Risks the call surfaced
Deal ramp execution
HighFour large Q1 deals + $230M Q2 deal (largest announced) ramps 'just initiated.' Revenue depends on FTE deployment pace, customer acceptance, and transition milestones. If ramps slip or require higher delivery costs, revenue misses and margin compression risk
Margin normalization & one-time costs
HighQ1 PAT declined 20.2% QoQ despite 24.2% revenue growth due to $24M one-time/integration costs ($6.5M acquisition, $10M hedge loss, $14M MTM loss to be realized Q2-Q3). Intangible amortization ($40M/year permanent) and finance costs on $550M term loan (2.99% post-tax) will persist. If normalization slows or deal margin profiles underperform, 15.5% EBIT guidance at risk
Encora margin sustainability
MediumEncora delivered 19.1% EBIT in Q1 (2-month window May-June); likely captured higher-margin ramp and seasonal tailwinds. Full-quarter and annual run-rate unknown. If Encora normalized margins drop to 16-17% (near consolidated target), blended margin upside diminishes. Also, $480M customer relationship intangibles ($40M/year amortization) will drag reported EBIT
Organic growth moderation
MediumOrganic CC sequential growth only 1.1% reported (5.2% ex-India govt/data center exits). This is below company's historical 20%+ CAGR and below 'robust growth' rhetoric. Suggests base business softness; reliance on large deal ramps to drive FY27 growth. If deal ramps compress or discretionary spending weakens industry-wide, full-year growth guidance at risk
Valuation & market multiple compression
MediumManagement has guided 'exceptional' FY27 growth and 'highest margin mid-cap' positioning, implying premium valuation expectations. However, delivered results show PAT growth (49.2% YoY) lagging revenue growth (49.9% YoY) and QoQ PAT declining 20.2%, signaling near-term margin pressure. If large deal ramps disappoint or one-time costs persist longer than guided, multiple compression risk
Management
Score 8/10. Clear and structured; Sudhir Singh leads with 10-year tenure recap, strategic AI positioning (Nuuron, Enterprise Autonomy), and specific deal examples. Acknowledges one-time costs transparently. Deflects on Encora order book details (only 2-month data) but promises Q2 update. Avoids hard Q2/Q3 guidance (uses 'robust' instead of %); justifiable given deal ramp timing uncertainty Strong: 9-year 21.7% revenue CAGR, 24.1% PAT CAGR. Delivered order book +44% YoY (beat 30% expectation). Encora integration 40% G&A reduction ahead of plan. $158M deal ramped in 4 months to 300+ FTEs. FY26 guidance met/beat. Q1 EBIT 16.0% ahead of 15.5% FY27 target. Track record of acquisition success (Cigniti, SLK Global, Incessant) credible
1 · Q2 FY27
$230M multi-year deal ramps; 20-30 additional teams; full revenue recognition tracking
2 · Q2 FY27
Integration cost normalization; hedge impacts reduce; standalone margins expand toward 17%
3 · Q3 FY27
Encora order book ramp; large deals in 11-20 client list scale from ₹20-50Cr to $50M+ buckets
Key risk: deal ramps (especially $230M deal signed for Q2) must execute on schedule to justify current growth narrative; margin recovery dependent on integration cost normalization by Q3.